Gross Margin % is calculated as gross profit divided by its revenue. Orgenesis's Gross Profit for the
three
months ended in Dec. 2021 was $-1.47 Mil. Orgenesis's Revenue for the
three
months ended in Dec. 2021 was $6.89 Mil. Therefore, Orgenesis's Gross Margin % for the quarter that ended in Dec. 2021 was -21.30%.
The historical rank and industry rank for Orgenesis's Gross Margin % or its related term are showing as below:
ORGS'
s Gross Margin % Range Over the Past 10 Years
Min: -300.13 Med: -19.7 Max: 42.65
Current: 20.68
During the past 13 years, the highestGross Margin % of Orgenesis was 42.65%. The lowest was -300.13%. And the median was -19.70%.
ORGS's Gross Margin % is ranked worse than 86.07% of 718
companies
in the Biotechnology industry
Industry Median: 61.23
vs ORGS: 20.68
Orgenesis had a gross margin of -21.30% for the quarter that ended in Dec. 2021 => No sustainable competitive advantage
The 5-Year average Growth Rate of Gross Margin for Orgenesis was 0.00% per year.
Orgenesis Gross Margin % Historical Data
The historical data trend for Orgenesis's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Orgenesis Annual Data
Trend
Nov12
Nov13
Nov14
Nov15
Nov16
Nov17
Nov18
Dec19
Dec20
Dec21
Gross Margin %
32.53
42.65
-211.93
-300.13
20.68
Orgenesis Quarterly Data
Feb17
May17
Aug17
Nov17
Feb18
May18
Aug18
Nov18
Mar19
Jun19
Sep19
Dec19
Mar20
Jun20
Sep20
Dec20
Mar21
Jun21
Sep21
Dec21
Gross Margin %
-83.10
45.14
28.64
17.89
-21.30
Competitive Comparison
For the Biotechnology subindustry, Orgenesis's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Orgenesis Gross Margin % Distribution
For the Biotechnology industry and Healthcare sector, Orgenesis's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Orgenesis's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Orgenesis (NAS:ORGS) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Orgenesis had a gross margin of -21.30% for the quarter that ended in Dec. 2021 => No sustainable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Orgenesis Gross Margin % Related Terms
Thank you for viewing the detailed overview of Orgenesis's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.
Orgenesis Inc is a part of the healthcare sector. It is a fully-integrated biopharmaceutical company focused on developing trans-differentiation technologies for diabetes and vertically integrating manufacturing that can optimize its abilities to scale-up its technologies for clinical trials and eventual commercialization. The group operates in two segments namely CDMO and POC. The company is also engaged in applying its disciplined execution to emerging technologies of other cell therapy markets in such areas as cell-based cancer immunotherapies and neurodegenerative diseases.
My Portfolios
Create New Portfolio
Portfolio Contest
My Gurus
Personalize
Premium Gurus 
0.03(1.43%) Volume: 54,822 4:00PM EDT
Email Alerts
Stock PDF
RSS
Website
Filings
Download
Manual of Stocks™ Web APP
NAS:ORGS has been successfully added to your 
